The molecular therapy of colorectal cancer

Molecular Aspects of Medicine

Volumn 31, Issue 2, 2010, Pages 171-178

  Waldner, Maximilian J ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antibodies: monoclonal; Antineoplastic agents; Colorectal neoplasms; Neovascularization: pathologic; Receptor: epidermal growth factor; Vascular endothelial growth factor A

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ARRY 162; BEVACIZUMAB; CETUXIMAB; EPITHELIAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR RECEPTOR; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 2206; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANITUMUMAB; PERIFOSINE; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VQD 0002; WNT PROTEIN; XL 147; XL 518;

ADENOCARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG MECHANISM; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MOLECULAR THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77951497951     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2010.02.005     Document Type: Review

References (80)

1. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
2. Becker C., Fantini M.C., Schramm C., Lehr H.-A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., Ito H., Nishimoto N., Yoshizaki K., Kishimoto T., Galle P.R., Blessing M., Rose-John S., Neurath M.F. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
3. Becker C., Fantini M.C., Neurath M.F. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 2006, 17:97-106.
4. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
5. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., Matthews V., Schmid R.M., Kirchner T., Arkan M.C., Ernst M., Greten F.R. Gp130-mediated stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009, 15:91-102.
6. Buerkle M.A., Pahernik S.A., Sutter A., Jonczyk A., Messmer K., Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br. J. Cancer 2002, 86:788-795.
7. Cao Y., Deng C., Townsend C.M., Ko T.C. TGF-beta inhibits Akt-induced transformation in intestinal epithelial cells. Surgery 2006, 140:322-329.
8. Capdevila J., Elez E., Macarulla T., Ramos F.J., Ruiz-Echarri M., Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev. 2009, 35:354-363.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., Thomas J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
11. Chow J.Y.C., Cabral J.A., Chang J., Carethers J.M. TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol. Ther. 2008, 7:1694-1699.
12. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
13. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
14. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
15. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
16. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J., Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10:501-507.
17. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20:4368-4380.
18. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
19. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
20. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
21. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
22. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
23. Ferrara N., Hillan K.J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discovery 2004, 3:391-400.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
25. Garber K. Drugging the Wnt pathway: problems and progress. J. Natl. Cancer Inst. 2009, 101:548-550.
26. Gatenby R.A., Silva A.S., Gillies R.J., Frieden B.R. Adaptive therapy. Cancer Res. 2009, 69:4894-4903.
27. Goldstein N.S., Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001, 92:1331-1346.
28. Greenberger L.M., Horak I.D., Filpula D., Sapra P., Westergaard M., Frydenlund H.F., Albaek C., Schrøder H., Ørum H. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 2008, 7:3598-3608.
29. Greenhough A., Smartt H.J.M., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
30. Griffioen G., Vasen H.F., Verspaget H.W., Lamers C.B. Familial adenomatous polyposis: from bedside to bench and vice versa. A tribute to the somatic cell geneticist P. Meera Khan. Cytogenet. Cell Genet. 1999, 86:125-129.
31. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.-Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
32. Hodivala-Dilke K.M., Reynolds A.R., Reynolds L.E. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res. 2003, 314:131-144.
33. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
34. Ikehara N., Semba S., Sakashita M., Aoyama N., Kasuga M., Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int. J. Cancer. 2005, 115:943-950.
35. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-17.
36. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
37. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA: Cancer J. Clin. 2009, 59:225-249.
38. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.-J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
39. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
40. Kizaka-Kondoh S., Tanaka S., Harada H., Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv. Drug. Deliv. Rev. 2009, 61:623-632.
41. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 2008, 7:90-100.
42. Koh M.Y., Spivak-Kroizman T.R., Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin. Cancer Res. 2009, 15:5945-5946.
43. Kupsch P., Henning B.F., Passarge K., Richly H., Wiesemann K., Hilger R.A., Scheulen M.E., Christensen O., Brendel E., Schwartz B., Hofstra E., Voigtmann R., Seeber S., Strumberg D. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 2005, 5:188-196.
44. Lin W.-W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
45. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA: Cancer J. Clin. 2009, 59:111-137.
46. MacDonald T.J., Taga T., Shimada H., Tabrizi P., Zlokovic B.V., Cheresh D.A., Laug W.E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001, 48:151-157.
47. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
48. Manegold P.C., Paringer C., Kulka U., Krimmel K., Eichhorn M.E., Wilkowski R., Jauch K.-W., Guba M., Bruns C.J. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 2008, 14:892-900.
49. Martin-Fernandez C., Bales J., Hodgkinson C., Welman A., Welham M.J., Dive C., Morrow C.J. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol. Cancer Res. 2009, 7:955-965.
50. Mayer R.J. Targeted therapy for advanced colorectal cancer - more is not always better. N. Engl. J. Med. 2009, 360:623-625.
51. Mayer A., Takimoto M., Fritz E., Schellander G., Kofler K., Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460.
52. Meuillet E.J., Ihle N., Baker A.F., Gard J.M., Stamper C., Williams R., Coon A., Mahadevan D., George B.L., Kirkpatrick L., Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol. Res. 2004, 14:513-527.
53. Miyazaki M., Furuya T., Shiraki A., Sato T., Oga A., Sasaki K. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res. 1999, 59:5283-5285.
54. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
55. Mousa S.A., Mohamed S., Wexler E.J., Kerr J.S. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist. Anticancer Res. 2005, 25:197-206.
56. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15:220-231.
57. Porebska I., Harlozińska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000, 21:105-115.
58. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., Vogelstein B., Kinzler K.W. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237.
59. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19:183-232.
60. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22:1201-1208.
61. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22:2954-2963.
62. Schreck R., Rapp U.R. Raf kinases: oncogenesis and drug discovery. Int. J. Cancer 2006, 119:2261-2271.
63. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., Leopold W.R., Saltiel A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5:810-816.
64. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
65. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 1997, 39:1-20.
66. Taketo M.M., Edelmann W. Mouse models of colon cancer. Gastroenterology 2009, 136:780-798.
67. Tenesa A., Dunlop M. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat. Rev. Genet. 2009, 10:353-358.
68. Thorstensen L., Lind G.E., Løvig T., Diep C.B., Meling G.I., Rognum T.O., Lothe R.A. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 2005, 7:99-108.
69. Tol J., Nagtegaal I.D., Punt C.J.A. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 2009, 361:98-99.
70. Van Cutsem E., Köhne C.-H., Hitre E., Zaluski J., Chang Chien C.-R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
71. Varner J.A., Cheresh D.A. Integrins and cancer. Curr. Opin. Cell Biol. 1996, 8:724-730.
72. Waldner M.J., Neurath M.F. Cytokines in colitis associated cancer: potential drug targets?. BSP: Inflammation Allergy - Drug Targets 2008, 7:187-194.
73. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 2009, 9:489-499.
74. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R., Project C.G. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
75. Wang H., Rajan S., Liu G., Chakrabarty S. Transforming growth factor beta suppresses beta-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner. Cancer Lett. 2008, 264:281-287.
76. Wang J., Yang L., Yang J., Kuropatwinski K., Wang W., Liu X.-Q., Hauser J., Brattain M.G. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 2008, 68:3152-3160.
77. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
78. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
79. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
80. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.